摘要
目的探讨聚乙二醇干扰素α-2a联合恩替卡韦对慢性乙型肝炎病人肝功能及肝纤维化的影响。方法将70例慢性乙型肝炎病人分为观察组和对照组,各35例。全部病人给予常规综合治疗,对照组采用恩替卡韦治疗,观察组采用聚乙二醇干扰素α-2a联合恩替卡韦治疗,比较两组病人肝功能及肝纤维化程度。结果观察组总有效为88.57%,对照组为62.86%,两组比较差异有统计学意义(χ~2=6.293,P<0.05);两组治疗后总胆红素(TBil)、丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、谷氨酰转肽酶(GGT)均显著降低(P<0.05);观察组治疗后AST、ALT、TBil、GGT显著低于对照组治疗后,差异有统计学意义(t=5.410、7.084、7.414、2.460,P<0.05);两组治疗后透明质酸酶(HA)、Ⅲ型前胶原(PCⅢ)、层连黏蛋白(LN)、IV型肽原(Ⅳ-C)均显著降低(P<0.05);观察组治疗后HA、PCⅢ、LN、Ⅳ-C显著低于对照组治疗后,差异有统计学意义(t=14.194、3.666、3.896、4.362,P<0.05);两组均未出现明显的全身或局部不良反应。结论聚乙二醇干扰素α-2a联合恩替卡韦能显著提高慢性乙型肝炎病人的肝功能,逆转肝纤维化进程。
Objective To investigate the effects of pegylated interferon a-2a combined with entecavir on liver function and hepatic fibrosis in patients with chronic hepatitis B.Methods70cases of chronic hepatitis B were divided into observation group(n=35)and control group(n=35).All patients were treated with conventional therapy.The control group used in treatment with entecavir.The observation group were treated with pegylated interferon a-2a combined with entecavir.Liver function and liver fibrosis in two groups were compared.Results The total effective of observation group was88.57%and the control group was62.86%.There were statistically significant differences between the two groups()(2=6.293,P<0.05).After treatment in the two groups of total bilirubin(TBil),alanine aminotransferase(ALT),aspartate aminotransferase(AST),valley ammonia acyl turn peptidase(GGT)were significantly decreased(P<0.05),but the observation group was significantly lower than the control group.The difference was statistically significant(^=5.410,7.084,7.414,2.460,P<0.05).After treatment,hyaluronidase(HA),type IH collagen(PC IH),the layer of mucin(LN)and type IV peptide(IV-C)were significantly decreased(P<0.05).And the observation group was significantly lower than the control group.The difference was statistically significant(t-14.194,3.666,3.896,4.362,P<0.05).There were no obvious systemic or local adverse reactions in the two groups.Conclusion Pegylated interferon a-2a combined with entecavir can significantly improve liver function in patients with chronic hepatitis B and reverse the process of hepatic fibrosis.
作者
李哲成
陈朝霞
吴昭颐
吴雅莉
邹震
LI Zhecheng;CHEN Zhaoxia;WU Zhaoyi;WU Yali;Z0U Zhen(Xiangya Medical College of Central South University Changsha Hunan 410013, China;Inspection Department of Hunan Cancer Hospital, Changsha,Hunan 410006,China;General Surgery Department of Hunan Provincial People rs Hospital, Changsha,Hunan 410005,China;Department of Clinical Pharmacy,Maternal and Child Health Hospital of Hunan Province, Changsha, Hunan 41000S,China;Department of Orthopedics The Affiliated Hospital of Hunan Academy of Traditional Chinese Medicine, Changsha, Hunan 410006, China)
出处
《安徽医药》
CAS
2017年第8期1490-1493,共4页
Anhui Medical and Pharmaceutical Journal
作者简介
通信作者:陈朝霞，女，副主任技师，研究方向：临床生化检验，E-mail:893003891@qq.com
